Who are GlaxoSmithKline?
GlaxoSmithKline (GSK) is one of the world’s largest healthcare companies, based in the United Kingdom and operating in over 150 countries worldwide.
Their product portfolio focuses on four core therapeutic areas:
- Respiratory, immunology and inflammation
- Oncology
- HIV
- Infectious diseases
GSK in Singapore
GSK describes itself as “the first global healthcare company to establish a presence in Singapore”.
- Operations in Singapore began in 1959 with the creation of a sales office.
- GSK then opened global manufacturing sites in Quality Road (in 1972) and Jurong (in 1982).
- R&D operations began in 2008, while manufacturing of vaccines at the Tuas site began in 2009.
In total, the company has invested more than S$2.5 billion in the country.
Today, Singapore is home to the company’s headquarters for both the International region and the Global General Medicines business.
There are also two GSK manufacturing sites: a global manufacturing supply site and a vaccines manufacturing facility.
The company employs over 1,300 people across these 3 sites.
Let’s now take a closer look at the company’s sites across Singapore…
GSK Sites in Singapore
GSK Asia House
This site is GSK’s corporate and commercial office in Singapore.
The company’s regional headquarters for the International biopharmaceutical business are based here, as well as the commercial operations for the Singapore market. It is also home to the global headquarters of the General Medicines business.
Check out this video for a virtual tour of the site:
https://www.youtube.com/watch?v=fyPGXrlVwQw
Jurong global manufacturing site
Facilities on the Jurong site were initially opened in 1982 for API manufacturing.
Over time, operations have expanded to include Small Molecule New Product Introduction (NPI). So today, as well as bulk API manufacturing, the site also delivers small batches of very active, high-value compounds.
There is also an R&D Pilot Plant within the site.
Medicines produced at the site treat conditions in therapeutic areas including HIV, oncology and respiratory diseases.
In 2014, the Jurong site commissioned the company’s first continuous processing plant using hybrid continuous-batch synthesis.
Then in 2019, new production facilities were opened on the site which included 2 continuous manufacturing lines.
Most recently, in 2021, a High Potency facility and laboratory (the first of their kind in Singapore) were opened to support manufacturing of cancer treatments.
This video follows Han Siong Chew, a Senior Operations Technician and gives a good overview of working at the Jurong site.
https://www.youtube.com/watch?v=oDdJmOUZBfI
Tuas global vaccines manufacturing facility
The Tuas site is a facility solely focused on the manufacture of paediatric vaccines. It is the first such plant in Asia and its opening in 2009 marked 50 years of GSK’s presence in Singapore.
Vaccines produced here are used to protect children from conditions such as pneumonia, meningitis and other invasive infections.
After further investment, the Tuas site has expanded to manufacture Hepatitis B vaccines for global supply. Commercial production is expected to commence in 2028.
These recent developments make this Singapore’s largest vaccine production site.
This video gives a look inside the Tuas site and the expansion of manufacturing.
https://www.youtube.com/watch?v=wyUaFcDW0KY
Partnerships
GSK has also invested in Singapore in other ways.
As an example, the GSK-Singapore Partnership for Green and Sustainable Manufacturing (which sees funding direct from the company as well as the EDB) provides researchers with funding to develop new ideas across all aspects of pharmaceutical manufacturing.
The NIHA (NUS Initiative to Improve Health in Asia) partnership between GSK and the EDB is “an integrative initiative to improve public health and healthcare delivery in Asia through improved research, governance and sustainable financing.”
The company also participates in a scholarship fund. The S$50m trust was set up by GSK and the EDB to fund talented young people to study science and technology programmes at top universities.
Recognition
In early 2017, GSK was one of 74 companies to receive the new “Human Capital Partner” symbol. The symbol is designed to highlight companies that are progressive and are actively working to develop staff. The three priorities that companies must commit to in order to receive the symbol are:
- Building a stronger Singaporean core by investing in all employees
- Selecting foreigners who compliment, to substitute, local workers
- Proactively transfer the expertise of foreign professionals to local workers
In 2026, GSK was recognised as one of Singapore’s Best Employers in the annual The Straits Times list.
Despite having manufacturing capabilities in 36 countries around the world, GSK has clearly shown that Singapore is an important country for their operations.
GSK was the first global healthcare company to come to Singapore but its enthusiasm hasn’t decreased over time. Ongoing and significant investment in sites here demonstrate that Singapore is an extremely important site for GSK.